

IN THE CLAIMS:

*Please AMEND the claims to read as set forth in the following listing of the claims:*

CLAIMS

1. (original) A cell support comprising an RGD-enriched gelatine in which the percentage of RGD motifs related to the total number of amino acids is at least 0.4 and if the RGD-enriched gelatine comprises 350 amino acids or more, each stretch of 350 amino acids contains at least one RGD motif.
2. (original) A cell support according to claim 1 in which in the RGD-enriched gelatine the percentage is at least 0.6, preferably at least 0.8, more preferably at least 1.0, more preferably at least 1.2 and most preferably at least 1.5.
3. (currently amended) A cell support according to claim 1 ~~or 2~~ in which in the RGD-enriched gelatine the number of RGD motifs is at least 4 per 250 amino acids.
4. (currently amended) A cell support according to claim 1 any of the preceding claims in which the RGD-enriched gelatine comprises at least 4 RGD motifs, preferably 6, more preferably 8, even more preferably 12 up to and including 16 RGD motifs.
5. (currently amended) A cell support according to claim 1 any of the preceding claims in which the RGD-enriched gelatine has a molecular weight of about 30 kDa to about 200 kDa.
6. (currently amended) A cell support according to claim 1 any of the preceding claims in which the RGD-enriched gelatine has a molecular weight of more than 60 kDa, preferably more than 70 kDa.

7. (currently amended) A cell support according to claim 1 ~~any of the preceding claims~~ in which the RGD-enriched gelatine has a molecular weight of less than about 150 kDa.
8. (currently amended) A cell support according to claim 1 ~~any of the preceding claims~~ in which the RGD-enriched gelatine comprises less than 5% hydroxyproline residues, preferably less than 3%.
9. (currently amended) A cell support according to claim 1 ~~any of the preceding claims~~ in which the RGD-enriched gelatine has a net positive charge at pH 7-7.5.
10. (currently amended) A cell support according to claim 1 ~~any of the preceding claims~~ in which the RGD-enriched gelatine consists for at least 80% of one or more parts of native human collagen sequences and said parts of native human collagen sequences have a length of at least 30 amino acids.
11. (original) A cell support according to claim 10 in which the RGD-enriched gelatine consists of one or more parts of one or more native human collagen sequences.
12. (original) An RGD-enriched gelatine in which the percentage of RGD motifs related to the total number of amino acids is at least 0.4 and if the RGD-enriched gelatine comprises 350 amino acids or more, each stretch of 350 amino acids contains at least one RGD motif, said gelatine consists for at least 80% of one or more parts of native human collagen sequences and said parts of native human collagen sequences having a length of at least 30 amino acids.

13. (original) An RGD-enriched gelatine according claim 12 wherein the RGD-enriched gelatine has a molecular weight of at most 10 kDa, preferably at most 5 kDa.
14. (currently amended) A cell support ~~according to any of claims 1-11 or~~ comprising an RGD-enriched gelatine according to claim 12, said cell support being a microcarrier.
15. (currently amended) A cell support ~~according to any of claims 1-11 or~~ comprising an RGD-enriched gelatine according to claim 12 ~~or 13~~, said cell support being selected from the group consisting of an RGD-enriched coated implant or transplant material, an RGD-enriched coated scaffold for tissue engineering, (part of) a dental product, (part of) a wound healing product, (part of) artificial skin matrix material and (part of) a tissue adhesive.
16. (original) Use of an RGD-enriched gelatine according to claim 12 as a component of drug delivery systems.
17. (original) Use of an RGD-enriched gelatine according to claim 13 for inhibition of cancer metastasis.
18. (currently amended) Use of an RGD-enriched gelatine according to claim 12 ~~or 13~~ for prevention of platelet aggregation.
19. (original) Use of an RGD-enriched gelatine according to claim 13 after surgery to prevent tissue adhesion.